|
業務類別
|
Biotechnology |
|
業務概覽
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercialRNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology. |
| 公司地址
| 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 551-8200 |
| 傳真號碼
| +1 617 551-8101 |
| 公司網頁
| https://www.alnylam.com |
| 員工數量
| 2500 |
| Dr. Yvonne L Greenstreet, MB.Ch.B. |
Director and Chief Executive Officer |
美元 1.40M |
06/04/2026 |
| Mr. Jeffrey V. Poulton |
Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 724.40K |
06/04/2026 |
| Dr. Pushkal P. Garg, M.D. |
Executive Vice President and Chief Research and Development Officer |
美元 767.90K |
06/04/2026 |
| Mr. Tolga Tanguler |
Chief Commercial Officer |
美元 698.00K |
06/04/2026 |
| Mr. Kevin Joseph Fitzgerald, PhD |
Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development |
-- |
06/04/2026 |
| Mr. Bryan A. Supran |
Executive Vice President, Chief Legal Officer and Secretary |
美元 190.40K |
06/04/2026 |
|
|
| Dr. Elliott Sigal, M.D.,PhD |
Independent Director |
06/04/2026 |
| Dr. Margaret A. Hamburg, M.D. |
Independent Director |
06/04/2026 |
| Ms. Amy W. Schulman |
Chairman of the Board |
06/04/2026 |
| Dr. Yvonne L Greenstreet, MB.Ch.B. |
Director and Chief Executive Officer |
06/04/2026 |
| Mr. David E.I. Pyott, M.A.,M.B.A. |
Independent Director |
06/04/2026 |
| Dr. Dennis A. Ausiello, M.D. |
Independent Director |
06/04/2026 |
| Mr. Peter N. Kellogg |
Independent Director |
06/04/2026 |
| Dr. Olivier Raymond Brandicourt, M.D. |
Independent Director |
06/04/2026 |
| Mr. Stuart A. Arbuckle |
Independent Director |
06/04/2026 |
| Ms. Colleen F. Reitan |
Independent Director |
06/04/2026 |
|
|
|
|
